COMP <GO>
NIVF vs MRK // NET PROFIT MARGIN
NewGenIvf Group Limited (Class A) (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: NIVF 1
— MRK 8
▲ NET PROFIT MARGIN LEADER: NIVF
LAST: $0.98 (-14.05%) • MKT CAP: $11.3M
net-margins
68.00%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
net-margins
28.10%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NIVF VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NIVF | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 74.80% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -32.80% | 20.70% | -53.50 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | 3.42% | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | 34.30% | -94.30 | MRK | /operating-margins <GO> |
| Net Profit Margin ACTIVE | 68.00% | 28.10% | +39.90 | NIVF | /net-margins <GO> |
| Revenue Growth (YoY) | -13.00% | 1.30% | -14.30 | MRK | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.63 | 5.19 | -4.56 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 7/9 | -4.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 23.5 | 51.7 | -28.20 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.3M | $361.02B | -$361.01B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NIVF REV | MRK REV | NIVF GROSS % | MRK GROSS % | NIVF FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.7M | $65.01B | 20.2% | 74.8% | -$11.1M | $12.36B |
| FY 2024 | $5.4M | $64.17B | 33.6% | 76.3% | -$8.3M | $18.10B |
| FY 2023 | $5.1M | $60.12B | — | — | -$1.8M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NIVF // BETA —
MRK // BETA 0.92